Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche LF, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Joseph N, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen Jose A, Foulkes S, Ahmed K, Thombrayil A, Kalonji D, Cloney-Clark S, Zhu M, Bennett C, Albert G, Marcheschi A, Plested JS, Neal S, Chau G, Cho I, Fries L, Glenn GM, Madhi SA. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M(TM) adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother 2024; 20: 2425147. [4.53] CRD COVID
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M(TM) adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomize
- Journal Articles
